Skip to main content Accessibility help

Updated European Consensus Statement on diagnosis and treatment of adult ADHD

  • J.J.S. Kooij (a1) (a2), D. Bijlenga (a1), L. Salerno (a3), R. Jaeschke (a4), I. Bitter (a5), J. Balázs (a6), J. Thome (a7), G. Dom (a8), S. Kasper (a9), C. Nunes Filipe (a10), S. Stes (a11), P. Mohr (a12), S. Leppämäki (a13), M. Casas (a14), J. Bobes (a15), J.M. Mccarthy (a16), V. Richarte (a17), A. Kjems Philipsen (a18), A. Pehlivanidis (a19), A. Niemela (a20), B. Styr (a21), B. Semerci (a22), B. Bolea-Alamanac (a23), D. Edvinsson (a24), D. Baeyens (a25), D. Wynchank (a1), E. Sobanski (a26), A. Philipsen (a27), F. McNicholas (a28), H. Caci (a29), I. Mihailescu (a30), I. Manor (a31), I. Dobrescu (a32), T. Saito (a33), J. Krause (a34), J. Fayyad (a35), J.A. Ramos-Quiroga (a36), K. Foeken (a37), F. Rad (a38), M. Adamou (a39), M. Ohlmeier (a40), M. Fitzgerald (a41), M. Gill (a42), M. Lensing (a43), N. Motavalli Mukaddes (a44), P. Brudkiewicz (a45), P. Gustafsson (a46), P. Tani (a47), P. Oswald (a48), P.J. Carpentier (a49), P. De Rossi (a50), R. Delorme (a51), S. Markovska Simoska (a52), S. Pallanti (a53), S. Young (a54), S. Bejerot (a55), T. Lehtonen (a56), J. Kustow (a57), U. Müller-Sedgwick (a58), T. Hirvikoski (a59), V. Pironti (a60), Y. Ginsberg (a61), Z. Félegyházy (a62), M.P. Garcia-Portilla (a63) and P. Asherson (a64)...


Background Attention-deficit/hyperactivity disorder (ADHD) is among the most common psychiatric disorders of childhood that often persists into adulthood and old age. Yet ADHD is currently underdiagnosed and undertreated in many European countries, leading to chronicity of symptoms and impairment, due to lack of, or ineffective treatment, and higher costs of illness.

Methods The European Network Adult ADHD and the Section for Neurodevelopmental Disorders Across the Lifespan (NDAL) of the European Psychiatric Association (EPA), aim to increase awareness and knowledge of adult ADHD in and outside Europe. This Updated European Consensus Statement aims to support clinicians with research evidence and clinical experience from 63 experts of European and other countries in which ADHD in adults is recognized and treated.

Results Besides reviewing the latest research on prevalence, persistence, genetics and neurobiology of ADHD, three major questions are addressed: (1) What is the clinical picture of ADHD in adults? (2) How should ADHD be properly diagnosed in adults? (3) How should adult ADHDbe effectively treated?

Conclusions ADHD often presents as a lifelong impairing condition. The stigma surrounding ADHD, mainly due to lack of knowledge, increases the suffering of patients. Education on the lifespan perspective, diagnostic assessment, and treatment of ADHD must increase for students of general and mental health, and for psychiatry professionals. Instruments for screening and diagnosis of ADHD in adults are available, as are effective evidence-based treatments for ADHD and its negative outcomes. More research is needed on gender differences, and in older adults with ADHD.


This is an open access article under the CC BY-NC-ND license

Corresponding author

*Corresponding author at: European Network Adult ADHD, VUMc, Amsterdam, EPA, The Netherlands. E-mail address:


Hide All
[1]Kooij, SJBejerot, SBlackwell, ACaci, HCasas-Brugue, MCarpentier, PJ et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry 2010; 10:67.
[2]Asherson, PBuitelaar, JFaraone, SVRohde, LAAdult attention-deficit hyperactivity disorder: key conceptual issues. Lancet Psychiatry 2016;3(6):568-578.
[3]Fayyad, JSampson, NAHwang, IAdamowski, TAguilar-Gaxiola, SAl-Hamzawi, A et al. The descriptive epidemiology of DSM-IV adult ADHD in the world health organization world mental health surveys. Atten Defic Hyperact Disord 2017;9(1):47-65.
[4]Faraone, SVDoyle, AEThe nature and heritability of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin North Am 2001;10(2): 299-2ix.
[5]Faraone, SVGenetics of adult attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004; 27:303-321.
[6]Sprich, SBiederman, JCrawford, MHMundy, EFaraone, SVAdoptive and biological families of children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2000;39(11):1432-1437.
[7]Moore, JFombonne, EPsychopathology in adopted and nonadopted children: a clinical sample. Am J Orthopsychiatry 1999;69(3):403-409.
[8]Gilger, JWPennington, BFDeFries, JCA twin study of the etiology of comorbidity: attention-deficit hyperactivity disorder and dyslexia. JAmAcadChild AdolescPsychiatry. 1992;31(2):343-348.
[9]Sherman, DKIacono, WGMcGue, MKAttention-deficit hyperactivity disorder dimensions: a twin study of inattention and impulsivity-hyperactivity. JAmAcadChild AdolescPsychiatry. 1997;36(6):745-753.
[10]Rietveld, MJHudziak, JJBartels, Mv B.C.E, Boomsma, DIHeritability of attention problems in children: longitudinal results from a study of twins, age 3 to 12. J Child Psychol Psychiatry 2004;45(3):577-588.
[11]Levy, FHay, DAMcStephen, MWood, CWaldman, IAttention-deficit hyperactivity disorder: a category or a continuum? Genetic analysis of a large-scale twin study. J Am Acad Child Adolesc Psychiatry 1997;36(6):737-744.
[12]Faraone, SVPerlis, RHDoyle, AESmoller, JWGoralnick, JJHolmgren, MA et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57(11):1313-1323.
[13]Stevens, SESonuga-Barke, EJKreppner, JMBeckett, CCastle, JColvert, E et al. Inattention/overactivity following early severe institutional deprivation: presentation and associations in early adolescence. J Abnorm Child Psychol 2008;36(3):385-398.
[14]Faraone, SVBiederman, JMonuteaux, MCToward guidelines for pedigree selection in genetic studies of attention deficit hyperactivity disorder. Genet Epidemiol 2000;18(1):1-16.
[15]Boomsma, DISaviouk, VHottenga, JJDistel, MAde Moor, MHVink, JM et al. Genetic epidemiology of attention deficit hyperactivity disorder (ADHD index) in adults. PLoS One 2010;5(5): e10621.
[16]van den Berg, SMWillemsen, Gde Geus, EJBoomsma, DIGenetic etiology of stability of attention problems in young adulthood. Am J Med Genet B Neuropsychiatr Genet 141B(1)2006; 55-60.
[17]Larsson, HAsherson, PChang, ZLjung, TFriedrichs, BLarsson, JO et al. Genetic and environmental influences on adult attention deficit hyperactivity disorder symptoms: a large Swedish population-based study of twins. Psychol Med 2013;43(1):197-207.
[18]Brikell, IKuja-Halkola, RLarsson, HHeritability of attention-deficit hyperactivity disorder in adults. Am J Med Genet B Neuropsychiatr Genet 2015.
[19]Merwood, AGreven, CUPrice, TSRijsdijk, FKuntsi, JMcLoughlin, G et al. Different heritabilities but shared etiological influences for parent, teacher and self-ratings of ADHD symptoms: an adolescent twin study. Psychol Med (Paris) 2013;43(9):1973-1984.
[20]Chang, ZLichtenstein, PAsherson, PJLarsson, HDevelopmental twin study of attention problems: high heritabilities throughout development. JAMA Psychiatry 2013;70(3):311-318.
[21]Larsson, HChang, ZD’Onofrio, BMLichtenstein, PThe heritability of clinically diagnosed attention deficit hyperactivity disorder across the lifespan. Psychol Med (Paris) 2013; 1-7.
[22]Faraone, SVLarsson, HGenetics of attention deficit hyperactivity disorder. Mol Psychiatry 2018.
[23]Li, DSham, PCOwen, MJHe, LMeta-analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD). Hum Mol Genet 2006;15(14):2276-2284.
[24]Gizer, IRFicks, CWaldman, IDCandidate gene studies of ADHD: a meta-analytic review. Hum Genet 2009;126(1):51-90.
[25]Kuntsi, JNeale, BMChen, WFaraone, SVAsherson, PThe IMAGE project: methodological issues for the molecular genetic analysis of ADHD. Behav Brain Funct 2006; 2:27.
[26]Neale, BMMedland, SERipke, SAsherson, PFranke, BLesch, KP et al. Meta-analysis of genome-wide association studies of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2010;49(9):884-897.
[27]Poelmans, GPauls, DLBuitelaar, JKFranke, BIntegrated genome-wide association study findings: identification of a neurodevelopmental network for attention deficit hyperactivity disorder. Am J Psychiatry 2011;168(4):365-377.
[28]Demontis, DWalters, RKMartin, JMattheisen, MAls, TDAgerbo, E et al. Discovery of the first genome-wide significant risk loci for ADHD. Nat Genet 2018 In Press.
[29]Ribases, MSanchez-Mora, CRamos-Quiroga, JABosch, RGomez, NNogueira, M et al. An association study of sequence variants in the forkhead box P2 (FOXP2) gene and adulthood attention-deficit/hyperactivity disorder in two European samples. Psychiatr Genet 2012;22(4):155-160.
[30]Middeldorp, CMHammerschlag, AROuwens, KGGroen-Blokhuis, MMPourcain, BSGreven, CU et al. A genome-wide association meta-analysis of Attention-Deficit/Hyperactivity disorder symptoms in population-based pediatric cohorts. J Am Acad Child Adolesc Psychiatry 2016;55(10):896-905 e6.
[31]Elia, JGai, XXie, HMPerin, JCGeiger, EGlessner, JT et al. Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes. Mol Psychiatry 2009;15(6):637-646.
[32]Williams, NMZaharieva, IMartin, ALangley, KMantripragada, KFossdal, R et al. Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis. Lancet 2010;376(9750):1401-1408.
[33]Williams, NMFranke, BMick, EAnney, RJFreitag, CMGill, M et al. Genome-wide analysis of copy number variants in attention deficit/hyperactivity disorder confirms the role of rare variants and implicates duplications at 15q13.3. Am J Psychiatry 2012;169(2):195-204.
[34]Elia, JGlessner, JTWang, KTakahashi, NShtir, CJHadley, D et al. Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat Genet 2012;44(1):78-84.
[35]Lesch, KPSelch, SRenner, TJJacob, CNguyen, TTHahn, T et al. Genome-wide copy number variation analysis in attention-deficit/hyperactivity disorder: association with neuropeptide Y gene dosage in an extended pedigree. Mol Psychiatry 2011;16(5):491-503.
[36]Franke, BHoogman, MArias Vasquez, AHeister, JGSavelkoul, PJNaber, M et al. Association of the dopamine transporter (SLC6A3/DAT1) gene 9-6 haplotype with adult ADHD. Am J Med Genet B Neuropsychiatr Genet 147B(8)2008; 1576-1579.
[37]Johansson, SHalmoy, AMavroconstanti, TJacobsen, KKLandaas, ETReif, A et al. Common variants in the TPH1 and TPH2 regions are not associated with persistent ADHD in a combined sample of 1,636 adult cases and 1,923 controls from four European populations. Am J Med Genet B Neuropsychiatr Genet 153B(5)2010; 1008-1015.
[38]Ribases, MHervas, ARamos-Quiroga, JABosch, RBielsa, AGastaminza, X et al. Association study of 10 genes encoding neurotrophic factors and their receptors in adult and child attention-deficit/hyperactivity disorder. Biol Psychiatry 2008;63(10):935-945.
[39]Ribases, MRamos-Quiroga, JAHervas, ABosch, RBielsa, AGastaminza, X et al. Exploration of 19 serotoninergic candidate genes in adults and children with attention-deficit/hyperactivity disorder identifies association for 5HT2A, DDC and MAOB. Mol Psychiatry 2009;14(1):71-85.
[40]Franke, BFaraone, SVAsherson, PBuitelaar, JBau, CHRamos-Quiroga, JA et al. The genetics of attention deficit/hyperactivity disorder in adults, a review. Mol Psychiatry 2012;17(10):960-987.
[41]Landaas, ETJohansson, SJacobsen, KKRibases, MBosch, RSanchez-Mora, C et al. An international multicenter association study of the serotonin transporter gene in persistent ADHD. Genes Brain Behav 2010;9(5):449-458.
[42]Sanchez-Mora, CRibases, MRamos-Quiroga, JACasas, MBosch, RBoreatti-Hummer, A et al. Meta-analysis of brain-derived neurotrophic factor p.Val66Met in adult ADHD in four European populations. Am J Med Genet B Neuropsychiatr Genet 153B(2)2010; 512-523.
[43]Banerjee, TDMiddleton, FFaraone, SVEnvironmental risk factors for attention-deficit hyperactivity disorder. Acta Paediatr 2007;96(9):1269-1274.
[44]Botting, NPowls, ACooke, RWMarlow, NAttention deficit hyperactivity disorders and other psychiatric outcomes in very low birthweight children at 12 years. JChild PsycholPsychiatry. 1997;38(8):931-941.
[45]Milberger, SBiederman, JFaraone, SVGuite, JTsuang, MTPregnancy, delivery and infancy complications and attention deficit hyperactivity disorder: issues of gene-environment interaction. Biol Psychiatry 1997;41(1):65-75.
[46]Cohen, MJMeador, KJBrowning, NMay, RBaker, GAClayton-Smith, J et al. Fetal antiepileptic drug exposure: adaptive and emotional/behavioral functioning at age 6years. Epilepsy Behav 2013;29(2):308-315.
[47]Gustavson, KYstrom, EStoltenberg, CSusser, ESuren, PMagnus, P et al. Smoking in pregnancy and child ADHD. Pediatrics 2017;139(2):.
[48]Depue, BEBurgess, GCBidwell, LCWillcutt, EGBanich, MTBehavioral performance predicts grey matter reductions in the right inferior frontal gyrus in young adults with combined type ADHD. Psychiatry Res 2010;182(3):231-237.
[49]Pironti, VALai, MCMuller, UDodds, CMSuckling, JBullmore, ET et al. Neuroanatomical abnormalities and cognitive impairments are shared by adults with attention-deficit/hyperactivity disorder and their unaffected first-degree relatives. Biol Psychiatry 2014;76(8):639-647.
[50]Makris, NSeidman, LJValera, EMBiederman, JMonuteaux, MCKennedy, DN et al. Anterior cingulate volumetric alterations in treatment-naive adults with ADHD: a pilot study. J Atten Disord 2010;13(4):407-413.
[51]Frodl, TSkokauskas, NMeta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects. Acta Psychiatr Scand 2012;125(2):114-126.
[52]Amico, FStauber, JKoutsouleris, NFrodl, TAnterior cingulate cortex gray matter abnormalities in adults with attention deficit hyperactivity disorder: a voxel-based morphometry study. Psychiatry Res 2011;191(1):31-35.
[53]Seidman, LJBiederman, JLiang, LValera, EMMonuteaux, MCBrown, A et al. Gray matter alterations in adults with attention-deficit/hyperactivity disorder identified by voxel based morphometry. Biol Psychiatry 2011;69(9):857-866.
[54]Almeida Montes, LGRicardo-Garcell, JLa Torre, LB Barajas DePrado Alcantara, HMartinez Garcia, RBFernandez-Bouzas, A et al. Clinical correlations of grey matter reductions in the caudate nucleus of adults with attention deficit hyperactivity disorder. J Psychiatry Neurosci 2010;35(4):238-246.
[55]Makris, NLiang, LBiederman, JValera, EMBrown, ABPetty, C et al. Toward defining the neural substrates of ADHD: a controlled structural MRI study in medication-naive adults. J Atten Disord 2015;19(11):944-953.
[56]Proal, EReiss, PTKlein, RGMannuzza, SGotimer, KRamos-Olazagasti, MA et al. Brain gray matter deficits at 33-year follow-up in adults with attention-deficit/hyperactivity disorder established in childhood. Arch Gen Psychiatry 2011;68(11):1122-1134.
[57]Ahrendts, JRusch, NWilke, MPhilipsen, AEickhoff, SBGlauche, V et al. Visual cortex abnormalities in adults with ADHD: a structural MRI study. World J Biol Psychiatry 2011;12(4):260-270.
[58]Duerden, EGTannock, RDockstader, CAltered cortical morphology in sensorimotor processing regions in adolescents and adults with attention-deficit/hyperactivity disorder. Brain Res 2012; 1445:82-91.
[59]Almeida, LGRicardo-Garcell, JPrado, HBarajas, LFernandez-Bouzas, AAvila, D et al. Reduced right frontal cortical thickness in children, adolescents and adults with ADHD and its correlation to clinical variables: a cross-sectional study. J Psychiatr Res 2010;44(16):1214-1223.
[60]Nakao, TRadua, JRubia, KMataix-Cols, DGray matter volume abnormalities in ADHD: voxel-based meta-analysis exploring the effects of age and stimulant medication. Am J Psychiatry 2011;168(11):1154-1163.
[61]Rubia, KAlegria, AABrinson, HBrain abnormalities in attention-deficit hyperactivity disorder: a review. Rev Neurol (Paris) 58(Suppl 1)2014 S3-16.
[62]Onnink, AMZwiers, MPHoogman, MMostert, JCKan, CCBuitelaar, J et al. Brain alterations in adult ADHD: effects of gender, treatment and comorbid depression. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology. 2014;24(3):397-409.
[63]Spencer, TJBrown, ASeidman, LJValera, EMMakris, NLomedico, A et al. Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies. J Clin Psychiatry 2013;74(9):902-917.
[64]Hoekzema, ECarmona, SRamos-Quiroga, JARicharte Fernandez, VPicado, MBosch, R et al. Laminar thickness alterations in the fronto-parietal cortical mantle of patients with attention-deficit/hyperactivity disorder. PLoS One 2012;7(12): e48286.
[65]Hoogman, MBuitelaar, JKFaraone, SVShaw, PFranke, Bgroup E-Aw, Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults - authors’ reply. Lancet Psychiatry 2017;4(6):440-441.
[66]Dramsdahl, MWesterhausen, RHaavik, JHugdahl, KPlessen, KJAdults with attention-deficit/hyperactivity disorder - a diffusion-tensor imaging study of the corpus callosum. Psychiatry Res 2012;201(2):168-173.
[67]Konrad A, Dielentheis Tf Fau - El Masri D, El Masri D Fau - Dellani PR, Dellani Pr Fau - Stoeter P, Stoeter P Fau - Vucurevic G, Vucurevic G Fau - Winterer G, et al. White matter abnormalities and their impact on attentional performance in adult attention-deficit/hyperactivity disorder. 2012(1433-8491 (Electronic)).
[68]Cortese, SImperati, DZhou, JProal, EKlein, RGMannuzza, S et al. White matter alterations at 33-year follow-up in adults with childhood attention-deficit/hyperactivity disorder. Biol Psychiatry 2013.
[69]Onnink, AMZwiers, MPHoogman, MMostert, JCDammers, JKan, CC et al. Deviant white matter structure in adults with attention-deficit/hyperactivity disorder points to aberrant myelination and affects neuropsychological performance. Prog Neuropsychopharmacol Biol Psychiatry 2015; 63:14-22.
[70]Shaw, PSudre, GWharton, AWeingart, DSharp, WSarlls, JWhite matter microstructure and the variable adult outcome of childhood attention deficit hyperactivity disorder. Neuropsychopharmacology 2015;40(3):746-754.
[71]Konrad, ADielentheis, TFEl Masri, DBayerl, MFehr, CGesierich, T et al. Disturbed structural connectivity is related to inattention and impulsivity in adult attention deficit hyperactivity disorder. Eur J Neurosci 2010;31(5):912-919.
[72]van Ewijk, HHeslenfeld, DJZwiers, MPFaraone, SVLuman, MHartman, CA et al. Different mechanisms of white matter abnormalities in attention-deficit/hyperactivity disorder: a diffusion tensor imaging study. J Am Acad Child Adolesc Psychiatry 2014;53(7): 790-9.e3.
[73]Liston, CCohen, MMTeslovich, TLevenson, DCasey, BJAtypical prefrontal connectivity in attention-deficit/hyperactivity disorder: pathway to disease or pathological end point?. Biol Psychiatry 2011;69(12):1168-1177.
[74]Cortese, SKelly, CChabernaud, CProal, EDi Martino, AMilham, MP et al. Toward systems neuroscience of ADHD: a meta-analysis of 55 fMRI studies. Am J Psychiatry 2012;169(10):1038-1055.
[75]Hart, HRadua, JNakao, TMataix-Cols, DRubia, KMeta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects. JAMA Psychiatry 2013;70(2):185-198.
[76]Hart, HRadua, JMataix-Cols, DRubia, KMeta-analysis of fMRI studies of timing in attention-deficit hyperactivity disorder (ADHD). Neurosci Biobehav Rev 2012;36(10):2248-2256.
[77]Yeo, BTKrienen, FMSepulcre, JSabuncu, MRLashkari, DHollinshead, M et al. The organization of the human cerebral cortex estimated by intrinsic functional connectivity. J Neurophysiol 2011;106(3):1125-1165.
[78]Castellanos, FXProal, ELarge-scale brain systems in ADHD: beyond the prefrontal-striatal model. Trends Cogn Sci (Regul Ed) 2012;16(1):17-26.
[79]Sudre, GSzekely, ESharp, WKasparek, SShaw, PMultimodal mapping of the brain’s functional connectivity and the adult outcome of attention deficit hyperactivity disorder. Proc Natl Acad Sci U S A. 2017;114(44):11787-11792.
[80]Wasserman, TWasserman, LDThe sensitivity and specificity of neuropsychological tests in the diagnosis of attention deficit hyperactivity disorder. Appl Neuropsychol Child 2012;1(2):90-99 doi: Epub 2012 Jul 10.
[81]Pettersson, RSoderstrom, SNilsson, KWDiagnosing ADHD in adults: an examination of the discriminative validity of neuropsychological tests and diagnostic assessment instruments. J Atten Disord 2015.
[82]Mostert, JCOnnink, AMKlein, MDammers, JHarneit, ASchulten, T et al. Cognitive heterogeneity in adult attention deficit/hyperactivity disorder: a systematic analysis of neuropsychological measurements. Eur Neuropsychopharmacol 2015;25(11):2062-2074.
[83]Barkley, RAFischer, MPredicting impairment in major life activities and occupational functioning in hyperactive children as adults: self-reported executive function (EF) deficits versus EF tests. Dev Neuropsychol 2011;36(2):137-161.
[84]Musso, MWGouvier, WDWhy is this so hard?: A review of detection of malingered ADHD in college students. J Atten Disord 2014;18(6):186-201.
[85]Bekker, EMOvertoom, CCKenemans, JLKooij, JJDe Noord, IBuitelaar, JK et al. Stopping and changing in adults with ADHD. Psychol Med 2005;35(6):807-816.
[86]Bekker, EMKenemans, JLHoeksma, MRTalsma, DVerbaten, MNThe pure electrophysiology of stopping. Int J Psychophysiol 2005.
[87]Seidman, LJValera, EMBush, GBrain function and structure in adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004;27(2):323-347.
[88]Seidman, LJDoyle, AFried, RValera, ECrum, KMatthews, LNeuropsychological function in adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004;27(2):261-282.
[89]Seidman, LJValera, EMMakris, NStructural brain imaging of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57(11):1263-1272.
[90]Swanson, JMElliott, GRGreenhill, LLWigal, TArnold, LEVitiello, B et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry 2007;46(8):1015-1027.
[91]Volkow, NDWang, GJNewcorn, JFowler, JSTelang, FSolanto, MV et al. Brain dopamine transporter levels in treatment and drug naive adults with ADHD. Neuroimage 2007;34(3):1182-1190.
[92]Retz, WKlein, RGAttention-deficit hyperactivity disorder (ADHD) in adults Key issues in mental health 2010, Karger Basel.
[93]Snyder, SMRugino, TAHornig, MStein, MAIntegration of an EEG biomarker with a clinician’s ADHD evaluation. Brain Behav 2015;5(4):e00330 doi: Epub 2015 Mar 5.
[94]Arns, MConners, CKKraemer, HCA decade of EEG Theta/Beta ratio research in ADHD: a meta-analysis. J Atten Disord 2013;17(5):374-383 doi: Epub 2012 Oct 19.
[95]Liechti, MDValko, LMuller, UCDohnert, MDrechsler, RSteinhausen, HC et al. Diagnostic value of resting electroencephalogram in attention-deficit/ hyperactivity disorder across the lifespan. Brain Topogr 2013;26(1): 135-51.
[96]Arns, MLoo, SKSterman, MBHeinrich, HKuntsi, JAsherson, P et al. Editorial Perspective: how should child psychologists and psychiatrists interpret FDA device approval? Caveat emptor. J Child Psychol Psychiatry 2016;57(5):656-658.
[97]Faraone, SVSergeant, JGillberg, CBiederman, JThe worldwide prevalence of ADHD: is it an American condition?. World Psychiatry 2003;2(2):104-113.
[98]Goodheart, CDA primer for ICD-10-CM users: psychological and behavioral conditions 2014, American Psychological Association Washington, DC.
[99]Kupfer, DJKuhl, EAWulsin, LPsychiatry’s integration with medicine: the role of DSM-5. Annu Rev Med 2013; 64:385-392 doi:
[100]Kooij, JJSBoonstra, AMSwinkels, SHBekker, EMde Noord, IBuitelaar, JKReliability, validity, and utility of instruments for self-report and informant report concerning symptoms of ADHD in adult patients. J Atten Disord 2008;11(4):445-458.
[101]Solanto, MVWasserstein, JMarks, DJMitchell, KJDiagnosis of ADHD in adults: What is the appropriate DSM-5 symptom threshold for hyperactivity-impulsivity?. J Atten Disord 2012;16(8):631-634.
[102]Kooij, JJBuitelaar, JKvan den Oord, EJFurer, JWRijnders, CAHodiamont, PPInternal and external validity of attention-deficit hyperactivity disorder in a population-based sample of adults. Psychol Med (Paris) 2005;35(6):817-827.
[103]Barkley, RABarkley adult ADHD rating Scale-IV (BAARS-IV) 2011, Guilford Press; US New York, NY.
[104]Skirrow, CAsherson, PEmotional lability, comorbidity and impairment in adults with attention-deficit hyperactivity disorder. J Affect Disord 147(1-3)2013; 80-86.
[105]Brown, TEA new understanding of ADHD in children and adults 2013, Routledge New York.
[106]Polanczyk, GLaranjeira, RZaleski, MPinsky, ICaetano, RRohde, LAADHD in a representative sample of the Brazilian population: estimated prevalence and comparative adequacy of criteria between adolescents and adults according to the item response theory. Int J Methods Psychiatr Res 2010;19(3):177-184.
[107]Faraone, SVKunwar, AAdamson, JBiederman, JPersonality traits among ADHD adults: implications of late-onset and subthreshold diagnoses. Psychol Med (Paris) 2009;39(4):685-693 doi: Epub 2008 Jun 30.
[108]Chandra, SBiederman, JFaraone, SVAssessing the validity of the age at onset criterion for diagnosing ADHD in DSM-5. J Atten Disord 2016; 27: 1087054716629717.
[109]Moffitt, TEHouts, RAsherson, PBelsky, DWCorcoran, DLHammerle, M et al. Is adult ADHD a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study. Am J Psychiatry 2015;172(10):967-977.
[110]Kieling, CKieling, RRRohde, LAFrick, PJMoffitt, TNigg, JT et al. The age at onset of attention deficit hyperactivity disorder. Am J Psychiatry 2010;167(1):14-16 doi:
[111]Morstedt, BCorbisiero, SBitto, HStieglitz, RDAttention-deficit/hyperactivity disorder (ADHD) in adulthood: concordance and differences between self- and informant perspectives on symptoms and functional impairment. PLoS One 2015;10(11): e0141342.
[112]Prevatt, FProctor, BBest, LBaker, LVan Walker, JTaylor, NWThe Positive Illusory Bias: Does it Explain Self-Evaluations in College Students With ADHD?. J Atten Disord 2012;16(3):235-243.
[113]APA. Diagnostic and Statistical Manual of Mental Disorders - DSM 5 - 5th ed. Force. APAD-T, editor. Washington, DC: American Psychiatric Publishing; 2013.
[114]Skirrow, CAsherson, PEmotional lability, comorbidity and impairment in adults with attention-deficit hyperactivity disorder. J Affect Disord 147(1-3)2013; 80-86.
[115]Surman, CBBiederman, JSpencer, TMiller, CAMcDermott, KMFaraone, SVUnderstanding deficient emotional self-regulation in adults with attention deficit hyperactivity disorder: a controlled study. Atten Defic Hyperact Disord 2013;5(3):273-281.
[116]Seli, PSmallwood, JCheyne, JASmilek, DOn the relation of mind wandering and ADHD symptomatology. Psychon Bull Rev 2015;22(3):629-636.
[117]Shaw, GAGiambra, LTask‐unrelated thoughts of college students diagnosed as hyperactive in childhood. Dev Neuropsychol 1993;9(1):17-30.
[118]Weyandt, LLIwaszuk, WFulton, KOllerton, MBeatty, NFouts, H et al. The internal restlessness scale: performance of college students with and without ADHD. J Learn Disabil 2003;36(4):382-389.
[119]Asherson, PClinical assessment and treatment of attention deficit hyperactivity disorder in adults. Expert Rev Neurother 2005;5(4):525-539.
[120]Mowlem, FDSkirrow, CReid, PMaltezos, SNijjar, SKMerwood, A et al. Validation of the mind excessively wandering scale and the relationship of mind wandering to impairment in adult ADHD. J Atten Disord 2016.
[121]Brown, TEADD/ADHD and impaired executive function in clinical practice. Curr Psychiatry Rep 2008;10(5):407-411.
[122]Barkley, RADifferential diagnosis of adults with ADHD: the role of executive function and self-regulation. J Clin Psychiatry 2010;71(7):e17.
[123]Bijlenga, DJasperse, MGehlhaar, SKSandra Kooij, JJObjective QbTest and subjective evaluation of stimulant treatment in adult attention deficit-hyperactivity disorder. Eur Psychiatry 2015;30(1):179-185 doi: Epub Aug 27.
[124]Toplak, MEWest, RFStanovich, KEPractitioner review: do performance-based measures and ratings of executive function assess the same construct?. J Child Psychol Psychiatry 2013;54(2):131-143.
[125]Barkley, RAFischer, MPredicting impairment in major life activities and occupational functioning in hyperactive children as adults: self-reported executive function (EF) deficits versus EF tests. Dev Neuropsychol 2011;36(2):137-161.
[126]de Graaf, RKessler, RCFayyad, Jten Have, MAlonso, JAngermeyer, M et al. The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey Initiative. Occup Environ Med 2008;65(12):835-842.
[127]Fredriksen, MDahl, AAMartinsen, EWKlungsoyr, OFaraone, SVPeleikis, DEChildhood and persistent ADHD symptoms associated with educational failure and long-term occupational disability in adult ADHD. Atten Defic Hyperact Disord 2014;6(2):87-99.
[128]Rogers, DCDittner, AJRimes, KAChalder, TFatigue in an adult attention deficit hyperactivity disorder population: a trans-diagnostic approach. Br J Clin Psychol 2017;56(1):33-52.
[129]Altszuler, ARPage, TFGnagy, EMCoxe, SArrieta, AMolina, BS et al. Financial dependence of young adults with childhood ADHD. J Abnorm Child Psychol 2016;44(6):1217-1229 doi:
[130]Bielefeld, MDrews, MPutzig, IBottel, LSteinbuchel, TDieris-Hirche, J et al. Comorbidity of Internet use disorder and attention deficit hyperactivity disorder: two adult case-control studies. J Behav Addict 2017;6(4):490-504 doi:
[131]Barkley, RACox, DA review of driving risks and impairments associated with attention-deficit/hyperactivity disorder and the effects of stimulant medication on driving performance. J Safety Res 2007;38(1):113-128.
[132]Dalsgaard, SOstergaard, SDLeckman, JFMortensen, PBPedersen, MGMortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet 2015;385(9983):2190-2196.
[133]Chang, ZQuinn, PDHur, KGibbons, RDSjolander, ALarsson, H et al. Association between medication use for Attention-deficit/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry 2017;74(6):597-603.
[134]Guendelman, MDAhmad, SMeza, JIOwens, EBHinshaw, SPChildhood attention-deficit/hyperactivity disorder predicts intimate partner victimization in young women. J Abnorm Child Psychol 2015.
[135]Buitelaar, NJPosthumus, JABuitelaar, JKADHD in childhood and/or adulthood as a risk factor for domestic violence or intimate partner violence: a systematic review. J Atten Disord 2015; 20: (1087054715587099):1087054715587099.
[136]Kaye, SGilsenan, JYoung, JTCarruthers, SAllsop, SDegenhardt, L et al. Risk behaviours among substance use disorder treatment seekers with and without adult ADHD symptoms. Drug Alcohol Depend 2014; 144:70-77.
[137]Chang, ZLichtenstein, PD’Onofrio, BMAlmqvist, CKuja-Halkola, RSjolander, A et al. Maternal age at childbirth and risk for ADHD in offspring: a population-based cohort study. Int J Epidemiol 2014;43(6):1815-1824 doi: Epub 2014 Oct 29.
[138]Hosain, GMBerenson, ABTennen, HBauer, LOWu, ZHAttention deficit hyperactivity symptoms and risky sexual behavior in young adult women. J Womens Health (Larchmt). 2012;21(4):463-468 doi: Epub 2 Feb 3.
[139]McClernon, FJKollins, SHADHD and smoking: from genes to brain to behavior. Ann N Y Acad Sci 2008; 1141:131-147.
[140]Furczyk, KThome, JAdult ADHD and suicide. Attent Defic Hyperact Disord. 2014;6(3):153-158.
[141]Swanson, ENOwens, EBHinshaw, SPPathways to self-harmful behaviors in young women with and without ADHD: a longitudinal examination of mediating factors. J Child Psychol Psychiatry 2014;55(5):505-515 Epub 2013 Dec 23.
[142]Ginsberg, YHirvikoski, TLindefors, NAttention deficit hyperactivity disorder (ADHD) among longer-term prison inmates is a prevalent, persistent and disabling disorder. BMC Psychiatry 2010; 10:112.
[143]Young, SGudjonsson, GAsherson, PTheobald, JOliver, BScott, C et al. Attention deficit hyperactivity disorder and critical incidents in a Scottish prison population. Pers Individ Dif 2009; 46:265-269.
[144]Bijlenga, Dvan der Heijden, KBBreuk, Mvan Someren, EJLie, MEBoonstra, AM et al. Associations between sleep characteristics, seasonal depressive symptoms, lifestyle, and ADHD symptoms in adults. J Atten Disord 2013;17(3):261-274.
[145]Spencer, TJFaraone, SVTarko, LMcDermott, KBiederman, JAttention-deficit/hyperactivity disorder and adverse health outcomes in adults. J Nerv Ment Dis 2014;202(10):725-731.
[146]Stickley, AKoyanagi, ATakahashi, HRuchkin, VInoue, YKamio, YAttention-deficit/hyperactivity disorder and physical multimorbidity: a population-based study. Eur Psychiatry 2017; 45:227-234.
[147]Instanes, JTKlungsoyr, KHalmoy, AFasmer, OBAdult ADHD, Haavik J.Comorbid somatic disease: a systematic literature review. J Atten Disord 2018;22(3):203-228.
[148]Hegvik, TAInstanes, JTHaavik, JKlungsoyr, KEngeland, AAssociations between attention-deficit/hyperactivity disorder and autoimmune diseases are modified by sex: a population-based cross-sectional study. Eur Child Adolesc Psychiatry 2017;5(10):017-1056.
[149]Cortese, SMoreira-Maia, CRSt Fleur, DMorcillo-Penalver, CRohde, LAFaraone, SVAssociation between ADHD and obesity: a systematic review and meta-analysis. Am J Psychiatry 2016;173(1):34-43.
[150]Asherson, PAkehurst, RKooij, JJHuss, MBeusterien, KSasane, R et al. Under diagnosis of adult ADHD: cultural influences and societal burden. J Atten Disord 16(5 Suppl)2012 20S-38S.
[151]Tegelbeckers, JBunzeck, NDuzel, EBonath, BFlechtner, HHKrauel, KAltered salience processing in attention deficit hyperactivity disorder. Hum Brain Mapp 2015;36(6):2049-2060.
[152]Bozhilova, NSMichelini, GKuntsi, JAsherson, PMind wandering perspective on attention-deficit/hyperactivity disorder. Neurosci Biobehav Rev 2018; 92:464-476.
[153]Polanczyk, GVSalum, GASugaya, LSCaye, ARohde, LAAnnual Research Review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. J Child Psychol Psychiatry 2015;56(3):345-365.
[154]Wood, DRReimherr, FWWender, PHJohnson, GEDiagnosis and treatment of minimal brain dysfunction in adults: a preliminary report. Arch Gen Psychiatry 1976;33(12):1453-1460.
[155]Weiss, GHechtman, LMilroy, TPsychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Psychiatry 1985; 24:211-220.
[156]Mannuzza, SKlein, RGAddalli, KAYoung adult mental status of hyperactive boys and their brothers: a prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1991;30(5):743-751.
[157]Lie, NFollow-ups of children with attention deficit hyperactivity disorder (ADHD). Review of literature. Acta Psychiatr Scand Suppl 1992; 368:1-40.
[158]Wender, PHWolf, LEWasserstein, JAdults with ADD: an overview. Ann N Y Acad Sci 931(pp 1-16)2001.
[159]Barkley, RAFischer, MSmallish, LFletcher, KThe persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol 2002;111(2):279-289.
[160]Mannuzza, SKlein, RGMoulton, JL 3rd Persistence of Attention-Deficit/Hyperactivity Disorder into adulthood: what have we learned from the prospective follow-up studies?. J Atten Disord 2003;7(2):93-100.
[161]Asherson, PChen, WCraddock, BTaylor, EAdult attention-deficit hyperactivity disorder: recognition and treatment in general adult psychiatry. Br J Psychiatry 2007; 190:4-5.
[162]Michielsen, MSemeijn, EComijs, HCvan de Ven, PBeekman, ATDeeg, DJ et al. Prevalence of attention-deficit hyperactivity disorder in older adults in the Netherlands. Br J Psychiatry 2012;201(4):298-305.
[163]Michielsen, Mde Kruif, JTComijs, HCvan Mierlo, SSemeijn, EJBeekman, AT et al. The burden of ADHD in older adults: a qualitative study. J Atten Disord 2015.
[164]Semeijn, EKooij, JJSComijs, HMichielsen, MDeeg, DJBeekman, ATAttention-deficit/hyperactivity disorder, physical health, and lifestyle in older adults. J Am Geriatr Soc 2013;61(6):882-887.
[165]Goodman, DWMitchell, SRhodewalt, LSurman, CBClinical presentation, diagnosis and treatment of attention-deficit hyperactivity disorder (ADHD) in older adults: a review of the evidence and its implications for clinical care. Drugs Aging 2016;33(1):27-36.
[166]Torgersen, TGjervan, BLensing, MBRasmussen, KOptimal management of ADHD in older adults. Neuropsychiatr Dis Treat 2016; 12:79-87.
[167]Kooij, JJMichielsen, MKruithof, HBijlenga, DADHD in old age: a review of the literature and proposal for assessment and treatment. Expert Rev Neurother 2016;16(12):1371-1381.
[168]Rucklidge, JJGender differences in attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2010;33(2):357-373.
[169]Barkley, RAMurphy, KRFischer, MADHD in adults: what the science says 2010, Guildford Press New York.
[170]Biederman, JMick, EFaraone, SVBraaten, EDoyle, ASpencer, T et al. Influence of gender on attention deficit hyperactivity disorder in children referred to a psychiatric clinic. Am J Psychiatry 2002;159(1):36-42.
[171]Vingilis, EErickson, PGToplak, MEKolla, NJMann, RESeeley, J et al. Attention deficit hyperactivity disorder symptoms, comorbidities, substance use, and social outcomes among men and women in a canadian sample. Biomed Res Int 2015; 2015: 982072.
[172]Quinn, POMadhoo, MA review of attention-deficit/hyperactivity disorder in women and girls: uncovering this hidden diagnosis. Prim Care Companion CNS Disord 2014;16(3):.
[173]Ptacek, RKuzelova, HPapezova, HStepankova, TAttention deficit hyperactivity disorder and eating disorders. Prague Med Rep 2010;111(3):175-181.
[174]Arnett, ABPennington, BFWillcutt, EGDeFries, JCOlson, RKSex differences in ADHD symptom severity. J Child Psychol Psychiatry 2015;56(6):632-639 doi: Epub 2014 Oct 4.
[175]Argumedo, GSSanz, CROlguin, HJExperimental models of developmental hypothyroidism. Horm Metab Res 2012;44(2):79-85 doi: Epub 2011 Dec 27.
[176]Fuller-Thomson, ELewis, DAAgbeyaka, SKAttention-deficit/hyperactivity disorder casts a long shadow: findings from a population-based study of adult women with self-reported ADHD. Child Care Health Dev 2016;42(6):918-927.
[177]Van Voorhees, EEMitchell, JTMcClernon, FJBeckham, JCKollins, SHSex, ADHD symptoms, and smoking outcomes: an integrative model. Med Hypotheses 2012;78(5):585-593.
[178]Faraone, SVBiederman, JMick, EThe age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med (Paris) 2006;36(2):159-165.
[179]Casey, BJJones, RMNeurobiology of the adolescent brain and behavior: implications for substance use disorders. J Am Acad Child Adolesc Psychiatry 2010;49(12):1189-1201 doi: quiz 285, Epub Oct 8.
[180]Singh, SPTransition of care from child to adult mental health services: the great divide. Curr Opin Psychiatry 2009;22(4):386-390 doi:
[181]While, AForbes, AUllman, RLewis, SMathes, LGriffiths, PGood practices that address continuity during transition from child to adult care: synthesis of the evidence. Child Care Health Dev 2004;30(5):439-452.
[182]NICE, Attention deficit hyperactivity disorder: diagnosis and management: national Insitute for Health and Care Excellence 2008.
[183]Nutt, DJFone, KAsherson, PBramble, DHill, PMatthews, K et al. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2007;21(1):10-41.
[184]Bolea-Alamanac, BNutt, DJAdamou, MAsherson, PBazire, SCoghill, D et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol (Oxford) 2014;28(3):179-203.
[185]Young, SAdamou, MAsherson, PCoghill, DColley, BGudjonsson, G et al. Recommendations for the transition of patients with ADHD from child to adult healthcare services: a consensus statement from the UK adult ADHD network. BMC Psychiatry 2016;16(301): doi:
[186]Singh, SPPaul, MFord, TKramer, TWeaver, TMcLaren, S et al. Process, outcome and experience of transition from child to adult mental healthcare: multiperspective study. Br J Psychiatry 2010;197(4):305-312 doi:
[187]Tatlow-Golden, MGavin, BMcNamara, NSingh, SFord, TPaul, M et al. Transitioning from child and adolescent mental health services with attention-deficit hyperactivity disorder in Ireland: case note review. Early Interv Psychiatry 2017.
[188]McNamara, NMcNicholas, FFord, TPaul, MGavin, BCoyne, I et al. Transition from child and adolescent to adult mental health services in the Republic of Ireland: an investigation of process and operational practice. Early Interv Psychiatry 2014;8(3):291-297 doi: Epub 2013 Jul 4.
[189]Swift, KDHall, CLMarimuttu, VRedstone, LSayal, KHollis, CTransition to adult mental health services for young people with Attention Deficit/Hyperactivity Disorder (ADHD): a qualitative analysis of their experiences. BMC Psychiatry 2013;13(74):.
[190]Hall, CLNewell, KTaylor, JSayal, KHollis, CServices for young people with attention deficit/hyperactivity disorder transitioning from child to adult mental health services: a national survey of mental health trusts in England. J Psychopharmacol (Oxford) 2015;29(1):39-42 doi: Epub 2014 Sep 18.
[191]Coghill, DServices for adults with ADHD: work in progress: commentary on. Specialist adult ADHD clinics in East Anglia. BJPsych Bull. 2015;39(3):140-143 doi:
[192]Sibley, MHRohde, LASwanson, JMHechtman, LTMolina, BSGMitchell, JT et al. Late-onset ADHD reconsidered with comprehensive repeated assessments between ages 10 and 25. Am J Psychiatry 2018;175(2):140-149.
[193]Faraone, SVBiederman, JCan attention-deficit/hyperactivity disorder onset occur in adulthood?. JAMA Psychiatry 2016;73(7):655-656.
[194]Caye, ASibley, MHSwanson, JMRohde, LALate-onset ADHD: understanding the evidence and building theoretical frameworks. Curr Psychiatry Rep 2017;19(12):106.
[195]Cooper, MHammerton, GCollishaw, SLangley, KThapar, ADalsgaard, S et al. Investigating late-onset ADHD: a population cohort investigation. J Child Psychol Psychiatry Allied Discip 2018;59(10):1105-1113.
[196]Ustun, BAdler, LARudin, CFaraone, SVSpencer, TJBerglund, P et al. The world health organization adult attention-deficit/hyperactivity disorder self-report screening scale for DSM-5. JAMA Psychiatry 2017;74(5):520-526.
[197]NICE, Diagnosis and management of ADHD in children, young people and adults 2018, London The British Psychological Society and The Royal College of Psychiatrists.
[198]Kooij, JJAdult ADHD: diagnostic assessment and treatment 3rd ed. 2013, Springer London.
[199]Ramos-Quiroga, JABosch, RRicharte, VValero, SGomez-Barros, NNogueira, M et al. Criterion and concurrent validity of Conners Adult ADHD Diagnostic Interview for DSM-IV (CAADID) Spanish version. [Spanish] Validez de criterio y concurrente de la version espanola de la Conners Adult ADHD Diagnostic Interview for DSM-IV. Rev Psiquiatr Salud Ment 2012;5(4):229-235.
[200]Rommelse, Nvan der Kruijs, MDamhuis, JHoek, ISmeets, SAntshel, KM et al. An evidenced-based perspective on the validity of attention-deficit/hyperactivity disorder in the context of high intelligence. Neurosci Biobehav Rev 2016; 71:21-47.
[201]Jacob, CPRomanos, JDempfle, AHeine, MWindemuth-Kieselbach, CKruse, A et al. Co-morbidity of adult attention-deficit/hyperactivity disorder with focus on personality traits and related disorders in a tertiary referral center. Eur Arch Psychiatry Clin Neurosci 2007;257(6):309-317 Epub 2007 Apr 1.
[202]Fayyad, JSampson, NAHwang, IAdamowski, TAguilar-Gaxiola, SAl-Hamzawi, A et al. The descriptive epidemiology of DSM-IV adult ADHD in the world health organization world mental health surveys. Atten Defic Hyperact Disord 2017;9(1):47-65.
[203]Faraone, SVAsherson, PBanaschewski, TBiederman, JBuitelaar, JKRamos-Quiroga, JA et al. Attention-deficit/hyperactivity disorder. Nat Rev Dis Primers 2015; 1:15020 doi:
[204]Roy, AHechtman, LArnold, LESibley, MHMolina, BSSwanson, JM et al. Childhood factors affecting persistence and desistence of attention-deficit/hyperactivity disorder symptoms in adulthood: results from the MTA. J Am Acad Child Adolesc Psychiatry 2016;55(11): doi: 937-44.e4, Epub Sep 2.
[205]Instanes, JTHaavik, JHalmoy, APersonality traits and comorbidity in adults with ADHD. J Atten Disord 2016;20(10):845-854 doi: Epub 2013 Nov 22.
[206]Skirrow, CMcLoughlin, GKuntsi, JAsherson, PBehavioral, neurocognitive and treatment overlap between attention-deficit/hyperactivity disorder and mood instability. Expert Rev Neurother 2009;9(4):489-503 doi:
[207]Corbisiero, SMorstedt, BBitto, HStieglitz, RDEmotional dysregulation in adults with attention-deficit/hyperactivity disorder-validity, predictability, severity, and comorbidity. J Clin Psychol 2017;73(1):99-112 doi: Epub 2016 May 6.
[208]Ferrer, MAndion, OMatali, JValero, SNavarro, JARamos-Quiroga, JA et al. Comorbid attention-deficit/hyperactivity disorder in borderline patients defines an impulsive subtype of borderline personality disorder. J Pers Disord 2010;24(6):812-822.
[209]O’Malley, GKMcHugh, LMac Giollabhui, NBramham, JCharacterizing adult attention-deficit/hyperactivity-disorder and comorbid borderline personality disorder: ADHD symptoms, psychopathology, cognitive functioning and psychosocial factors. Eur Psychiatry 2016; 31:29-36 doi: Epub Dec 3.
[210]Van Dijk, FELappenschaar, MKan, CCVerkes, RJBuitelaar, JKSymptomatic overlap between attention-deficit/hyperactivity disorder and borderline personality disorder in women: the role of temperament and character traits. Compr Psychiatry 2012;53(1):39-47.
[211]Gillberg, CDeficits in attention, motor control, and perception: a brief review. Arch Dis Child 2003;88(10):904-910.
[212]Foreman, DMForeman, DPrendergast, MMinty, BIs clinic prevalence of ICD-10 hyperkinesis underestimated? Impact of increasing awareness by a questionnaire screen in an UK clinic. Eur Child Adolesc Psychiatry 2001;10(2):130-134.
[213]von Polier, GGVloet, TDHerpertz-Dahlmann, BADHD and delinquency--a developmental perspective. Behav Sci Law 2012;30(2):121-139.
[214]Young, SMoss, DSedgwick, OFridman, MHodgkins, PA meta-analysis of the prevalence of attention deficit hyperactivity disorder in incarcerated populations. Psychol Med (Paris) 2015;45(2):247-258.
[215]Young, SThome, JADHD and offenders. World J Biol Psychiatry 12(Suppl 1)2011; 124-128.
[216]Young, SGoodwin, EAttention-deficit/hyperactivity disorder in persistent criminal offenders: the need for specialist treatment programs. Expert Rev Neurother 2010;10(10):1497-1500 doi:
[217]D’Amelio, RRetz, WPhilipsen, ARösler, MPsychoedukation und Coaching ADHS im Erwachsenenalter Manual zur Leitung von Patienten- und Angehörigengruppen 2009, Urban & Fischer Elsevier München.
[218]Hirvikoski, TWaaler, ELindstrom, TBolte, SJokinen, JCognitive behavior therapy-based psychoeducational groups for adults with ADHD and their significant others (PEGASUS): an open clinical feasibility trial. Atten Defic Hyperact Disord 2015;7(1):89-99.
[219]Hirvikoski, TLindström, TCarlsson, JWaaler, EJokinen, JBölte, SPsychoeducational groups for adults with ADHD and their significant others (PEGASUS): a pragmatic multicenter and randomized controlled trial. Eur Psychiatry 2017;9(44):141-152.
[220]Volkow, NDSwanson, JMClinical practice: adult attention deficit-hyperactivity disorder. N Engl J Med 2013;369(20):1935-1944.
[221]Bushe, CDay, KReed, VKarlsdotter, KBerggren, LPitcher, A et al. A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients. J Psychopharmacol 2016;30(5):444-458.
[222]Cortese, SAdamo, NDel Giovane, CMohr-Jensen, CHayes, AJCarucci, S et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 2018;5(9):727-738.
[223]Koesters, MBecker, TKilian, RFegert, JMWeinmann, SLimits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol (Oxford) 2009;23(7):733-744.
[224]Faraone, SVGlatt, SJA comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 2010;71(6):754-763.
[225]Castells, XRamos-Quiroga, JARigau, DBosch, RNogueira, MVidal, X et al. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs 2011;25(2):157-169.
[226]Castells, XRamos-Quiroga, JABosch, RNogueira, MCasas, MAmphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 6)2011 CD007813.
[227]Cunill, RCastells, XTobias, ACapella, DAtomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression. Pharmacoepidemiol Drug Saf 2013;22(9):961-969.
[228]Philipsen, AJans, TGraf, EMatthies, SBorel, PColla, M et al. Effects of group psychotherapy, individual counseling, methylphenidate, and placebo in the treatment of adult Attention-Deficit/Hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry 2015;72(12):1199-1210 doi:
[229]Chang, ZLichtenstein, PD’Onofrio, BMSjolander, ALarsson, HSerious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study. JAMA Psychiatry 2014;71(3):319-325.
[230]Lichtenstein, PLarsson, HMedication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 2013;368(8):776.
[231]Chen, QSjolander, ARuneson, BD’Onofrio, BMLichtenstein, PLarsson, HDrug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. BMJ 2014; 348:g3769.
[232]Chang, ZD’Onofrio, BMQuinn, PDLichtenstein, PLarsson, HMedication for attention-deficit/hyperactivity disorder and risk for depression: a nationwide longitudinal cohort study. Biol Psychiatry 2016;80(12):916-922.
[233]Chang, ZLichtenstein, PHalldner, LD’Onofrio, BSerlachius, EFazel, S et al. Stimulant ADHD medication and risk for substance abuse. J Child Psychol Psychiatry Allied Discip 2014;55(8):878-885.
[234]Sharman, JPennick, MLisdexamfetamine prodrug activation by peptidase-mediated hydrolysis in the cytosol of red blood cells. Neuropsychiatr Dis Treat 2014; 10:2275-2280.
[235]Setyawan, JHodgkins, PGuerin, AGauthier, GCloutier, MWu, EQ et al. Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis. J Med Econ 2013;16(7):962-975.
[236]Adler, LAGoodman, DWKollins, SHWeisler, RHKrishnan, SZhang, Y et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2008;69(9):1364-1373.
[237]Wigal, TBrams, MGasior, MGao, JSquires, LGiblin, J et al. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct 2010; 6:34.
[238]Dupaul, GJWeyandt, LLRossi, JSVilardo, BAO’Dell, SMCarson, KM et al. Double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in college students with ADHD. J Atten Disord 2012;16(3):202-220.
[239]Maneeton, NManeeton, BSuttajit, SReungyos, JSrisurapanont, MMartin, SDExploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD. Drug design. development and therapy. 2014; 8:1685-1693.
[240]Coghill, DRCaballero, BSorooshian, SCivil, RA systematic review of the safety of lisdexamfetamine dimesylate. CNS Drugs 2014;28(6):497-511.
[241]Adler, LADirks, BDeas, PFRaychaudhuri, ADauphin, MRLasser, RA et al. Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2013;74(7):694-702.
[242]Epstein, TPatsopoulos, NAWeiser, MImmediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 9)2014 CD005041.
[243]Martinez-Raga, JKnecht, CSzerman, NMartinez, MIRisk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. CNS Drugs 2013;27(1):15-30.
[244]Coghill, DBanaschewski, TZuddas, APelaz, AGagliano, ADoepfner, MLong-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies. BMC Psychiatry 2013; 13:237.
[245]Mick, EMcManus, DDGoldberg, RJMeta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology. 2013;23(6):534-541.
[246]Westover, ANHalm, EADo prescription stimulants increase the risk of adverse cardiovascular events?: a systematic review. BMC Cardiovasc Disord 2012; 12:41.
[247]Habel, LACooper, WOSox, CMChan, KAFireman, BHArbogast, PG et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA : J Am Med Assoc 2011;306(24):2673-2683.
[248]Schelleman, HBilker, WBKimmel, SEDaniel, GWNewcomb, CGuevara, JP et al. Methylphenidate and risk of serious cardiovascular events in adults. Am J Psychiatry 2012;169(2):178-185.
[249]Shin, JYRoughead, EEPark, BJPratt, NLCardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ 2016; 353:i2550.
[250]Asherson, PBushe, CSaylor, KTanaka, YDeberdt, WUpadhyaya, HEfficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials. J Psychopharmacol (Oxford) 2014;28(9):837-846.
[251]Asherson P, Young S, Adamou M, Bolea B, Coghill D, Gudjonsson G, et al. Handbook for Attention Deficit Hyperactivity Disorder in Adults. UKAAN, Springer Healthcare Communications; 2013.
[252]Ginsberg, YAhlqvist-Rastad, JAM, KBarroso, JBergquist, FBrodd, G et al. Läkemedel vid adhd – behandlingsrekommendation. Information från Läkemedelsverket 2)2016; 13-23.
[253]Quinn, PDChang, ZHur, KGibbons, RDLahey, BBRickert, ME et al. ADHD medication and substance-related problems. Am J Psychiatry 2017;174(9):877-885.
[254]Adler, LALiebowitz, MKronenberger, WQiao, MRubin, RHollandbeck, M et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety 2009;26(3):212-221.
[255]Bangs, MEEmslie, GJSpencer, TJRamsey, JLCarlson, CBartky, EJ et al. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol 2007;17(4):407-420.
[256]Posey, DJMcDougle, CJGuanfacine and guanfacine extended release: treatment for ADHD and related disorders. CNS Drug Rev 2007;13(4):465-474.
[257]Huss, MChen, WLudolph, AGGuanfacine extended release: a new pharmacological treatment option in Europe. Clin Drug Investig 2016;36(1):1-25.
[258]Butterfield, MESaal, JYoung, BYoung, JLSupplementary guanfacine hydrochloride as a treatment of attention deficit hyperactivity disorder in adults: a double blind, placebo-controlled study. Psychiatry Res 2016; 236:136-141.
[259]Kollins, SHJain, RBrams, MSegal, SFindling, RLWigal, SB et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics 2011;127(6): e1406-13.
[260]Jain, RSegal, SKollins, SHKhayrallah, MClonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2011;50(2):171-179.
[261]Palumbo, DRSallee, FRPelham, WE Jr.Bukstein, OGDaviss, WBMcDermott, MPClonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry 2008;47(2):180-188.
[262]Hazell, PLStuart, JEA randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry 2003;42(8):886-894.
[263]Maneeton, NManeeton, BIntaprasert, SWoottiluk, PA systematic review of randomized controlled trials of bupropion versus methylphenidate in the treatment of attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat 2014; 10:1439-1449.
[264]Hamedi, MMohammdi, MGhaleiha, AKeshavarzi, ZJafarnia, MKeramatfar, R et al. Bupropion in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind study. Acta Med Iran 2014;52(9):675-680.
[265]Ghanizadeh, AA systematic review of reboxetine for treating patients with attention deficit hyperactivity disorder. Nord J Psychiatry 2015;69(4):241-248.
[266]Riahi, FTehrani-Doost, MShahrivar, ZAlaghband-Rad, JEfficacy of reboxetine in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial. Hum Psychopharmacol 25(7-8)2010; 570-576.
[267]Otasowie, JCastells, XEhimare, UPSmith, CHTricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev 9)2014 CD006997.
[268]Prince, JBWilens, TEBiederman, JSpencer, TJMillstein, RPolisner, DA et al. A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2000;10(3):193-204.
[269]Weiss, MHechtman, LAdult, ARGA randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry 2006;67(4):611-619.
[270]Arnold, VKFeifel, DEarl, CQYang, RAdler, LAA 9-week, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy and safety of modafinil as treatment for adults with ADHD. J Atten Disord 2014;18(2):133-144.
[271]Wang, GJVolkow, NDWigal, TKollins, SHNewcorn, JHTelang, F et al. Long-term stimulant treatment affects brain dopamine transporter level in patients with attention deficit hyperactive disorder. PLoS One 2013;8(5): e63023.
[272]Cavero, IGuillon, JMSafety pharmacology assessment of drugs with biased 5-HT(2B) receptor agonism mediating cardiac valvulopathy. J Pharmacol Toxicol Methods 2014;69(2):150-161.
[273]Droogmans, SKerkhove, DCosyns, BVan Camp, GRole of echocardiography in toxic heart valvulopathy. Eur J Echocardiogr 2009;10(4):467-476.
[274]Seixas, MWeiss, MMuller, USystematic review of national and international guidelines on attention-deficit hyperactivity disorder. J Psychopharmacol (Oxford) 2012;26(6):753-765.
[275]Sobanski, EBruggemann, DAlm, BKern, SDeschner, MSchubert, T et al. Psychiatric comorbidity and functional impairment in a clinically referred sample of adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci 2007;257(7):371-377.
[276]Sharma, ACouture, JA review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother 2014;48(2):209-225.
[277]Bazire, SPsychotropic drug directory 2010 2010, HealthComm UK Ltd Aberdeen.
[278]Viktorin, ARyden, EThase, MEChang, ZLundholm, CD’Onofrio, BM et al. The risk of treatment-emergent mania with methylphenidate in bipolar disorder. Am J Psychiatry 2016 appiajp201616040467.
[279]Cunill, RCastells, XTobias, ACapella, DPharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence. J Psychopharmacol 2015;29(1):15-23.
[280]Steinhausen, HCBisgaard, CSubstance use disorders in association with attention-deficit/hyperactivity disorder, co-morbid mental disorders, and medication in a nationwide sample. Eur Neuropsychopharmacol 2014;24(2):232-241.
[281]Levin, FRMariani, JJSpecker, SMooney, MMahony, ABrooks, DJ et al. Extended-release mixed amphetamine salts vs placebo for comorbid adult Attention-Deficit/Hyperactivity disorder and cocaine use disorder: a randomized clinical trial. JAMA Psychiatry 2015;72(6):593-602.
[282]Konstenius, MJayaram-Lindstrom, NGuterstam, JBeck, OPhilips, BFranck, JMethylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial. Addiction 2014;109(3):440-449.
[283]Skoglund, CBrandt, LAlmqvist, CD’Onofrio, BMKonstenius, MFranck, J et al. Factors associated with adherence to methylphenidate treatment in adult patients with attention-deficit/hyperactivity disorder and substance use disorders. J Clin Psychopharmacol 2016;36(3):222-228.
[284]Cobos, J Perez de losSinol, NPerez, VTrujols, JPharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction. Br J Clin Pharmacol 2014;77(2):337-356.
[285]Crunelle, CLvan den Brink, WMoggi, FKonstenius, MFranck, JLevin, FR et al. International consensus statement on screening, diagnosis and treatment of substance use disorder patients with comorbid attention Deficit/Hyperactivity disorder. Eur Addict Res 2018;24(1):43-51.
[286]Torgersen, TGjervan, BRasmussen, KVaaler, ANordahl, HMPrevalence of comorbid substance use disorder during long-term central stimulant treatment in adult ADHD. Adhd Atten Deficit Hyperact Disord 2013;5(1):59-67.
[287]Klassen, LJBilkey, TSKatzman, MChokka, PComorbid attention Deficit/Hyperactivity disorder and substance use disorder: treatment considerations. Curr Drug Abuse Rev 2012.
[288]Cheung, CHFrazier-Wood, ACAsherson, PRijsdijk, FKuntsi, JShared cognitive impairments and aetiology in ADHD symptoms and reading difficulties. PLoS One 2014;9(6): e98590.
[289]Rabiner, DLAnastopoulos, ADCostello, EJHoyle, RHMcCabe, SESwartzwelder, HSThe misuse and diversion of prescribed ADHD medications by college students. J Atten Disord 2009;13(2):144-153.
[290]Besag, FMADHD treatment and pregnancy. Drug Saf: Int J Med Toxicol Drug Exp 2014;37(6):397-408.
[291]Dideriksen, DPottegard, AHallas, JAagaard, LDamkier, PFirst trimester in utero exposure to methylphenidate. Basic Clin Pharmacol Toxicol 2013;112(2):73-76.
[292]Pottegard, AHallas, JAndersen, JTLøkkegaard, ECDideriksen, DAagaard, L et al. First-trimester exposure to methylphenidate: a population-based cohort study. J Clin Psychiatry 2014;75(1):e88-e93.
[293]Huybrechts, KFBroms, GChristensen, LBEinarsdottir, KEngeland, AFuru, K et al. Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations: a cohort study from the international pregnancy safety study consortium. JAMA Psychiatry 2018;75(2):167-175.
[294]Diav-Citrin, OShechtman, SArnon, JWajnberg, RBorisch, CBeck, E et al. Methylphenidate in pregnancy: a multicenter, prospective, comparative, observational study. J Clin Psychiatry 2016;77(9):1176-1181.
[295]Bro, SPKjaersgaard, MIParner, ETSorensen, MJOlsen, JBech, BH et al. Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy. Clin Epidemiol 2015; 7:139-147.
[296]Haervig, KBMortensen, LHHansen, AVStrandberg-Larsen, KUse of ADHD medication during pregnancy from 1999 to 2010: a Danish register-based study. Pharmacoepidemiol Drug Saf 2014;23(5):526-533.
[297]McAllister-Williams, RHBaldwin, DSCantwell, REaster, AGilvarry, EGlover, V et al. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. J Psychopharmacol 2017;31(5):519-552.
[298]Bolea-Alamanac, BMGreen, AVerma, GMaxwell, PDavies, SJMethylphenidate use in pregnancy and lactation: a systematic review of evidence. Br J Clin Pharmacol 2014;77(1):96-101.
[299]Larsen, ERDamkier, PPedersen, LHFenger-Gron, JMikkelsen, RLNielsen, RE et al. Use of psychotropic drugs during pregnancy and breast-feeding. Acta Psychiatr Scand Suppl 2015; 445:1-28.
[300]Freeman, MP. ADHD and pregnancy. Am J Psychiatry 2014;171(7):723-728.
[301]Atomoxetine [Internet]. U.S. National Library of Medicine. Date accessed: 22.10.2017. Available from:
[302]Guanfacine [Internet]. U.S. National Library of Medicine. Date accessed: 22.10.2017. Available from:
[303]Clonidine [Internet]. U.S. National Library of Medicine. Date accessed: 22.10.2017. Available from:
[304]Lisdexamfetamine [Internet]. U.S. National Library of Medicine. Date accessed: 22.10.2017. Available from:
[305]Bupropion [Internet]. U.S. National Library of Medicine. Date accessed: 22.10.2017. Available from:
[306]Van der Heijden, KBSmits, MGVan Someren, EJGunning, WBIdiopathic chronic sleep onset insomnia in attention-deficit/hyperactivity disorder: a circadian rhythm sleep disorder. Chronobiol Int 2005;22(3):559-570.
[307]van Veen, MMKooij, JJBoonstra, AMGordijn, MCvan Someren, EJDelayed circadian rhythm in adults with attention-deficit/hyperactivity disorder and chronic sleep-onset insomnia. Biol Psychiatry 2010;67(11):1091-1096.
[308]Kooij, JJBijlenga, DThe circadian rhythm in adult attention-deficit/hyperactivity disorder: current state of affairs. Exp Rev Neurother. 2013;13(10):1107-1116.
[309]Kidwell, KMVan Dyk, TRLundahl, ANelson, TDStimulant medications and sleep for youth with ADHD: a meta-analysis. Pediatrics 2015;136(6):1144-1153.
[310]Snitselaar, MASmits, MGvan der Heijden, KBSpijker, JSleep and circadian rhythmicity in adult ADHD and the effect of stimulants. J Atten Disord 2017;21(1):14-26.
[311]Barrett, JRTracy, DKGiaroli, GTo sleep or not to sleep: a systematic review of the literature of pharmacological treatments of insomnia in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2013;23(10):640-647.
[312]Van der Heijden, KBSmits, MGVan Someren, EJWRidderinkhof, KRGunning, WBEffect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia. J Am Acad Child Adolesc Psychiatry 2007;46(2):233-241.
[313]Hirvikoski, TWaaler, EAlfredsson, JPihlgren, CHolmstrom, AJohnson, A et al. Reduced ADHD symptoms in adults with ADHD after structured skills training group: results from a randomized controlled trial. Behav Res Ther 2011;49(3):175-185.
[314]Young, SEmilsson, BSigurdsson, JFKhondoker, MPhilipp-Wiegmann, FBaldursson, G et al. A randomized controlled trial reporting functional outcomes of cognitive-behavioural therapy in medication-treated adults with ADHD and comorbid psychopathology. Eur Arch Psychiatry Clin Neurosci 2017;267(3):267-276.
[315]Jensen, CMAmdisen, BLJorgensen, KJArnfred, SMCognitive behavioural therapy for ADHD in adults: systematic review and meta-analyses. Atten Defic Hyperact Disord 2016;8(1):3-11 doi: Epub 2016 Jan 22.
[316]Arnold, LEHodgkins, PCaci, HKahle, JYoung, SEffect of treatment modality on long-term outcomes in attention-deficit/hyperactivity disorder: a systematic review. PLoS One 2015;10(2): e0116407 doi: 2015.
[317]Philipsen, APsychotherapy in adult attention deficit hyperactivity disorder: implications for treatment and research. Expert rev. 2012;12(10):1217-1225.
[318]Mongia, MHechtman, LCognitive behavior therapy for adults with attention-deficit/hyperactivity disorder: a review of recent randomized controlled trials. Curr Psychiatry Rep 2012;14(5):561-567.
[319]Safren, SAOtto, MWSprich, SWinett, CLWilens, TEBiederman, JCognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behav Res Ther 2005;43(7):831-842.
[320]Safren, SASprich, SMimiaga, MJSurman, CKnouse, LGroves, M et al. Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. JAMA 2010;304(8):875-880.
[321]Young, SKhondoker, MEmilsson, BSigurdsson, JFPhilipp-Wiegmann, FBaldursson, G et al. Cognitive-behavioural therapy in medication-treated adults with attention-deficit/hyperactivity disorder and co-morbid psychopathology: a randomized controlled trial using multi-level analysis. Psychol Med (Paris) 2015;45(13):2793-2804 doi: Epub 2015 May 29.
[322]Emilsson, BGudjonsson, GSigurdsson, JFBaldursson, GEinarsson, EOlafsdottir, H et al. Cognitive behaviour therapy in medication-treated adults with ADHD and persistent Symptoms: a randomized controlled trial. BMC Psychiatry 2011;11(116):.
[323]Young, SBramham, JCognitive-behavioural therapy for ADHD in adolescents and adults: a psychological guide to practice 2nd edition ed 2012, John Wiley & Sons Ltd Chichester.
[324]Knouse, LESafren, SACurrent status of cognitive behavioral therapy for adult attention-deficit hyperactivity disorder. Psychiatric Clin North Am 2010;33(3):497-509.
[325]Newark, PEStieglitz, RDTherapy-relevant factors in adult ADHD from a cognitive behavioural perspective. Atten Defic Hyperact Disord 2010;2(2):59-72.
[326]Torrente, FLopez, PAlvarez Prado, DKichic, RCetkovich-Bakmas, MLischinsky, A et al. Dysfunctional cognitions and their emotional, behavioral, and functional correlates in adults with attention deficit hyperactivity disorder (ADHD): is the cognitive-behavioral model valid?. J Atten Disord 2014;18(5):412-424 doi: Epub 2012 May 24.
[327]Kubik, JAEfficacy of ADHD coaching for adults with ADHD. J Atten Disord 2010;13(5):442-453 doi: Epub 2009 Mar 10.
[328]Prevatt, FYelland, SAn empirical evaluation of ADHD coaching in college students. J Atten Disord 2015;19(8):666-677 doi: Epub 2013 Mar 18.
[329]Hepark, SJanssen, Lde Vries, ASchoenberg, PLDonders, RKan, CC et al. The efficacy of adapted MBCT on core symptoms and executive functioning in adults with ADHD: a preliminary randomized controlled trial. J Atten Disord 2015; 20: 1087054715613587.
[330]Schoenberg, PLHepark, SKan, CCBarendregt, HPBuitelaar, JKSpeckens, AEEffects of mindfulness-based cognitive therapy on neurophysiological correlates of performance monitoring in adult attention-deficit/hyperactivity disorder. Clin Neurophysiol 2014;125(7):1407-1416.
[331]Cairncross, MMiller, CJThe effectiveness of mindfulness-based therapies for ADHD: a meta-analytic review. J Atten Disord 2016.
[332]Braun, SZeidler, JLinder, REngel, SVerheyen, FGreiner, WTreatment costs of attention deficit hyperactivity disorder in Germany. Eur J Health Econ 2013;14(6):939-945.
[333]Swensen, ABirnbaum, HGBen Hamadi, RGreenberg, PCremieux, PYSecnik, KIncidence and costs of accidents among attention-deficit/hyperactivity disorder patients. J Adolesc Health 2004;35(4):346 e1-9.
[334]Birnbaum, HGKessler, RCLowe, SWSecnik, KGreenberg, PELeong, SA et al. Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin 2005;21(2):195-206.
[335]Marchetti, AMagar, RLau, HMurphy, ELJensen, PSConners, CK et al. Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. Clin Ther 2001;23(11):1904-1921.
[336]Matza, LSParamore, CPrasad, MA review of the economic burden of ADHD. Cost effectiveness and resource allocation: C/E. 2005; 3:5.
[337]Daley, DJacobsen, RHLange, AMSørensen, AWalldorf J. Costing adult attention deficit hyperactivity disorder 2015, Oxford University Press New York.
[338]Fredriksen, MHalmoy, AFaraone, SVHaavik, JLong-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies. Eur Neuropsychopharmacol 2013;23(6):508-527.
[339]Gilmore, AMilne, RMethylphenidate in children with hyperactivity: review and cost-utility analysis. Pharmacoepidemiol Drug Saf 2001;10(2):85-94.
[340]King, SGriffin, SHodges, ZWeatherly, HAsseburg, CRichardson, G et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Assess (Rockv) 2006;10(23): iii-iv, xiii-146.
[341]Narayan, SHay, JCost effectiveness of methylphenidate versus AMP/DEX mixed salts for the first-line treatment of ADHD. Expert Rev Pharmacoecon Outcomes Res 2004;4(6):625-634.
[342]Zupancic, JMiller, ARaina, PLee, SKlassen, AOlsen, LPart 3: economic evaluation of pharmaceutical and psychological/behavioural therapies for attention-deficit/hyperactivity disordeMiller, ALee, SKRaina, P editors. Review of therapies for attention-deficit/hyperactivity disorde 1998, Canadian Coordinating Office for Health Technology Assessment Ottawa, Canada.
[343]Donnelly, MHaby, MMCarter, RAndrews, GVos, TCost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder. Aust N Z J Psychiatry 2004;38(8):592-601.
[344]Wu, EQHodgkins, PBen-Hamadi, RSetyawan, JXie, JSikirica, V et al. Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review. CNS Drugs 2012;26(7):581-600.
[345]Lebowitz, MSStigmatization of ADHD: a developmental review. J Atten Disord 2016;20(3):199-205.
[346]Baeyens, DMoniquet, ADanckaerts, Mvan der Oord, S[A comparative study of the structural stigmatisation of ADHD and autism spectrum disorder in Flemish newspapers]. Tijdschr Psychiatr 2017;59(5):269-277.
[347]Corrigan, PWShapiro, JRMeasuring the impact of programs that challenge the public stigma of mental illness. Clin Psychol Rev 2010;30(8):907-922.
[348]Mueller, AKFuermaier, ABMKoerts, JTucha, LStigma in attention deficit hyperactivity disorder. Atten Defic Hyperact Disord 2012;4(3):101-114.
[349]McKeague, LHennessy, EO’Driscoll, CHeary, CRetrospective accounts of self-stigma experienced by young people with attention-deficit/hyperactivity disorder (ADHD) or depression. Psychiatr Rehabil J 2015;38(2):158-163.
[350]Fuermaier, ABTucha, LMueller, AKKoerts, JHauser, JLange, KW et al. Stigmatization in teachers towards adults with attention deficit hyperactivity disorder. Springerplus 2014; 3:26.
[351]Tatlow-Golden, MPrihodova, LGavin, BCullen, WMcNicholas, FWhat do general practitioners know about ADHD? Attitudes and knowledge among first-contact gatekeepers: systematic narrative review. BMC Fam Pract 2016;17(1):129.
[352]Brohan, EHenderson, CWheat, KMalcolm, EClement, SBarley, EA et al. Systematic review of beliefs, behaviours and influencing factors associated with disclosure of a mental health problem in the workplace. BMC Psychiatry 2012; 12:11.
[353]CADDRA, Canadian ADHD practice guidelines third edition 2011, Canadian Attention Deficit Hyperactivity Disorder Resource Alliance Toronto, ON.